{
    "Trade/Device Name(s)": [
        "HemosIL ReadiPlasTin"
    ],
    "Submitter Information": "Instrumentation Laboratory Co.",
    "510(k) Number": "K122584",
    "Predicate Device Reference 510(k) Number(s)": [
        "K070005"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GJS",
        "GIS"
    ],
    "Summary Letter Date": "March 15, 2013",
    "Summary Letter Received Date": "March 18, 2013",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR864.7750",
        "21CFR864.7340"
    ],
    "Regulation Name(s)": [
        "Prothrombin time test",
        "Fibrinogen test"
    ],
    "Analyte Class(es)": [
        "coagulation",
        "hematology"
    ],
    "Analyte(s)": [
        "Prothrombin Time (PT)",
        "Fibrinogen"
    ],
    "Specimen Type(s)": [
        "Human citrated plasma"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        "ACL TOP Family of analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Absorbance clot detection",
        "Recombinant human tissue factor-based assay"
    ],
    "Methodologies": [
        "Quantitative determination",
        "PT-based method"
    ],
    "Submission Type(s)": [
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for HemosIL ReadiPlasTin recombinant thromboplastin reagent for PT and fibrinogen measurement on ACL TOP analyzers",
    "Indications for Use Summary": "In vitro diagnostic thromboplastin reagent for quantitative determination of Prothrombin Time and Fibrinogen in human citrated plasma, used for evaluating extrinsic coagulation pathway and monitoring oral Vitamin K antagonist therapy on ACL TOP analyzers",
    "fda_folder": "Hematology"
}